402 related articles for article (PubMed ID: 26592324)
1. Thiol redox biology of trypanosomatids and potential targets for chemotherapy.
Leroux AE; Krauth-Siegel RL
Mol Biochem Parasitol; 2016; 206(1-2):67-74. PubMed ID: 26592324
[TBL] [Abstract][Full Text] [Related]
2. Targeting Trypanothione Metabolism in Trypanosomatids.
González-Montero MC; Andrés-Rodríguez J; García-Fernández N; Pérez-Pertejo Y; Reguera RM; Balaña-Fouce R; García-Estrada C
Molecules; 2024 May; 29(10):. PubMed ID: 38792079
[TBL] [Abstract][Full Text] [Related]
3. Recent Advancement in the Search of Innovative Antiprotozoal Agents Targeting Trypanothione Metabolism.
Saccoliti F; Di Santo R; Costi R
ChemMedChem; 2020 Dec; 15(24):2420-2435. PubMed ID: 32805075
[TBL] [Abstract][Full Text] [Related]
4. Structural insights into the enzymes of the trypanothione pathway: targets for antileishmaniasis drugs.
Colotti G; Baiocco P; Fiorillo A; Boffi A; Poser E; Chiaro FD; Ilari A
Future Med Chem; 2013 Oct; 5(15):1861-75. PubMed ID: 24144416
[TBL] [Abstract][Full Text] [Related]
5. Cynaropicrin targets the trypanothione redox system in Trypanosoma brucei.
Zimmermann S; Oufir M; Leroux A; Krauth-Siegel RL; Becker K; Kaiser M; Brun R; Hamburger M; Adams M
Bioorg Med Chem; 2013 Nov; 21(22):7202-9. PubMed ID: 24080104
[TBL] [Abstract][Full Text] [Related]
6. Parasite-specific trypanothione reductase as a drug target molecule.
Krauth-Siegel RL; Inhoff O
Parasitol Res; 2003 Jun; 90 Suppl 2():S77-85. PubMed ID: 12709793
[TBL] [Abstract][Full Text] [Related]
7. Identification and binding mode of a novel Leishmania Trypanothione reductase inhibitor from high throughput screening.
Turcano L; Torrente E; Missineo A; Andreini M; Gramiccia M; Di Muccio T; Genovese I; Fiorillo A; Harper S; Bresciani A; Colotti G; Ilari A
PLoS Negl Trop Dis; 2018 Nov; 12(11):e0006969. PubMed ID: 30475811
[TBL] [Abstract][Full Text] [Related]
8. Molecular studies on trypanothione reductase: an antiparasitic target enzyme.
Walsh C; Bradley M; Nadeau K
Curr Top Cell Regul; 1992; 33():409-17. PubMed ID: 1354149
[No Abstract] [Full Text] [Related]
9. An Overview on Target-Based Drug Design against Kinetoplastid Protozoan Infections: Human African Trypanosomiasis, Chagas Disease and Leishmaniases.
Kourbeli V; Chontzopoulou E; Moschovou K; Pavlos D; Mavromoustakos T; Papanastasiou IP
Molecules; 2021 Jul; 26(15):. PubMed ID: 34361781
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanism underlying antileishmanial effect of oxabicyclo[3.3.1]nonanones: inhibition of key redox enzymes of the pathogen.
Saudagar P; Saha P; Saikia AK; Dubey VK
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):569-77. PubMed ID: 24002022
[TBL] [Abstract][Full Text] [Related]
11. Structure-guided approach to identify a novel class of anti-leishmaniasis diaryl sulfide compounds targeting the trypanothione metabolism.
Colotti G; Saccoliti F; Gramiccia M; Di Muccio T; Prakash J; Yadav S; Dubey VK; Vistoli G; Battista T; Mocci S; Fiorillo A; Bibi A; Madia VN; Messore A; Costi R; Di Santo R; Ilari A
Amino Acids; 2020 Feb; 52(2):247-259. PubMed ID: 31037461
[TBL] [Abstract][Full Text] [Related]
12. Enzymes of the trypanothione metabolism as targets for antitrypanosomal drug development.
Schmidt A; Krauth-Siegel RL
Curr Top Med Chem; 2002 Nov; 2(11):1239-59. PubMed ID: 12171583
[TBL] [Abstract][Full Text] [Related]
13. The parasite-specific trypanothione metabolism of trypanosoma and leishmania.
Krauth-Siegel RL; Meiering SK; Schmidt H
Biol Chem; 2003 Apr; 384(4):539-49. PubMed ID: 12751784
[TBL] [Abstract][Full Text] [Related]
14. The trypanothione system and its implications in the therapy of trypanosomatid diseases.
Flohé L
Int J Med Microbiol; 2012 Oct; 302(4-5):216-20. PubMed ID: 22889611
[TBL] [Abstract][Full Text] [Related]
15. Genetic and chemical analyses reveal that trypanothione synthetase but not glutathionylspermidine synthetase is essential for Leishmania infantum.
Sousa AF; Gomes-Alves AG; Benítez D; Comini MA; Flohé L; Jaeger T; Passos J; Stuhlmann F; Tomás AM; Castro H
Free Radic Biol Med; 2014 Aug; 73():229-38. PubMed ID: 24853758
[TBL] [Abstract][Full Text] [Related]
16. Binding to large enzyme pockets: small-molecule inhibitors of trypanothione reductase.
Persch E; Bryson S; Todoroff NK; Eberle C; Thelemann J; Dirdjaja N; Kaiser M; Weber M; Derbani H; Brun R; Schneider G; Pai EF; Krauth-Siegel RL; Diederich F
ChemMedChem; 2014 Aug; 9(8):1880-91. PubMed ID: 24788386
[TBL] [Abstract][Full Text] [Related]
17. Flavoprotein structure and mechanism. 5. Trypanothione reductase and lipoamide dehydrogenase as targets for a structure-based drug design.
Krauth-Siegel RL; Schöneck R
FASEB J; 1995 Sep; 9(12):1138-46. PubMed ID: 7672506
[TBL] [Abstract][Full Text] [Related]
18. Peptoid inhibition of trypanothione reductase as a potential antitrypanosomal and antileishmanial drug lead.
Chan C; Yin H; McKie JH; Fairlamb AH; Douglas KT
Amino Acids; 2002 Jun; 22(4):297-308. PubMed ID: 12107758
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of plumbagin and its derivative as potential modulators of redox thiol metabolism of Leishmania parasite.
Sharma N; Shukla AK; Das M; Dubey VK
Parasitol Res; 2012 Jan; 110(1):341-8. PubMed ID: 21717278
[TBL] [Abstract][Full Text] [Related]
20. Identification of Novel Chemical Scaffolds Inhibiting Trypanothione Synthetase from Pathogenic Trypanosomatids.
Benítez D; Medeiros A; Fiestas L; Panozzo-Zenere EA; Maiwald F; Prousis KC; Roussaki M; Calogeropoulou T; Detsi A; Jaeger T; Šarlauskas J; Peterlin Mašič L; Kunick C; Labadie GR; Flohé L; Comini MA
PLoS Negl Trop Dis; 2016 Apr; 10(4):e0004617. PubMed ID: 27070550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
